Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients
- Authors
- Kang, Minkyoung; Kim, Kyung Im; Song, Young-cheon; Shin, Wan Gyoon; Oh, Jung Mi
- Issue Date
- Oct-2012
- Publisher
- TAYLOR & FRANCIS LTD
- Keywords
- Anthracycline; Cardiotoxicity; Dexrazoxane; Pediatric; Prevention
- Citation
- JOURNAL OF CHEMOTHERAPY, v.24, no.5, pp 292 - 296
- Pages
- 5
- Journal Title
- JOURNAL OF CHEMOTHERAPY
- Volume
- 24
- Number
- 5
- Start Page
- 292
- End Page
- 296
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/11834
- DOI
- 10.1179/1973947812Y.0000000038
- ISSN
- 1120-009X
1973-9478
- Abstract
- Anthracyclines play a major role in chemotherapeutic regimens for a variety of pediatric cancers, but produce undesirable dose-related cardiotoxicity. Dexrazoxane reduces early myocardial injury during anthracycline treatment, but data remain insufficient to fully understand its cardioprotective effectiveness in treating pediatric cancers and additional research is necessary to find efficient methods of dexrazoxane administration. Therefore, we retrospectively evaluated the cardioprotective effect of dexrazoxane against anthracyclines in 258 pediatric cancer patients who had received any anthracyclines from January 1997 to May 2005 at a tertiary teaching hospital in Korea. The results of this study suggest that the early use of dexrazoxane protects against the development of cardiotoxicity during anthracycline treatment in pediatric cancer patients. Further studies involving larger pediatric cancer patients are needed to evaluate the cardioprotective effect of dexrazoxane at higher cumulative doses of anthracyclines and on late-onset cardiotoxicity in long-term survivors.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/11834)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.